Search Results - "Jukema, J Wouter"
-
1
Effects of fatty acids on T cell function: role in atherosclerosis
Published in Nature reviews cardiology (01-12-2021)“…T cells are among the most common cell types present in atherosclerotic plaques and are increasingly being recognized as a central mediator in atherosclerosis…”
Get full text
Journal Article -
2
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Published in The New England journal of medicine (29-11-2018)“…Among patients who had had an acute coronary syndrome, the risk of death from coronary heart disease, nonfatal myocardial infarction, stroke, or unstable…”
Get full text
Journal Article -
3
EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study
Published in European journal of preventive cardiology (20-09-2021)“…To provide contemporary data on the implementation of European guideline recommendations for lipid-lowering therapies (LLTs) across different settings and…”
Get full text
Journal Article -
4
High-Sensitivity Cardiac Troponin Concentration and Risk of First-Ever Cardiovascular Outcomes in 154,052 Participants
Published in Journal of the American College of Cardiology (01-08-2017)“…High-sensitivity assays can quantify cardiac troponins I and T (hs-cTnI, hs-cTnT) in individuals with no clinically manifest myocardial injury. The goal of…”
Get full text
Journal Article -
5
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Published in The New England journal of medicine (18-06-2015)“…In this trial, patients with an acute coronary syndrome within the previous 10 days were randomly assigned to simvastatin plus either ezetimibe or placebo. At…”
Get full text
Journal Article -
6
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE3Leiden.CETP mice
Published in European heart journal (21-08-2017)“…Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hypercholesterolaemia and…”
Get full text
Journal Article -
7
Vein graft failure: from pathophysiology to clinical outcomes
Published in Nature reviews cardiology (01-08-2016)“…Key Points Thrombosis, constrictive remodelling, intimal hyperplasia, and unstable atherosclerotic lesions are the critical mechanisms contributing to vein…”
Get full text
Journal Article -
8
Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
Published in The New England journal of medicine (20-04-2017)“…In six trials comparing the anti–PCSK9 antibody bococizumab with placebo, the reduction in LDL cholesterol at 12 weeks was 55.2 percentage points lower with…”
Get full text
Journal Article -
9
Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism
Published in The New England journal of medicine (29-06-2017)“…A double-blind, randomized, placebo-controlled, parallel-group trial aimed to determine whether levothyroxine provided clinical benefits in older persons with…”
Get full text
Journal Article -
10
Heart rate variability and first cardiovascular event in populations without known cardiovascular disease: meta-analysis and dose-response meta-regression
Published in Europace (London, England) (01-05-2013)“…Heart rate variability (HRV) is associated with cardiovascular disease (CVD) in individuals with known CVD. It is less clear whether HRV is associated with a…”
Get full text
Journal Article -
11
Body fat distribution, in particular visceral fat, is associated with cardiometabolic risk factors in obese women
Published in PloS one (28-09-2017)“…Body fat distribution is, next to overall obesity, an important risk factor for cardiometabolic outcomes in the general population. In particular, visceral…”
Get full text
Journal Article -
12
Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice[S]
Published in Journal of lipid research (01-03-2020)“…Atherosclerosis-related CVD causes nearly 20 million deaths annually. Most patients are treated after plaques develop, so therapies must regress existing…”
Get full text
Journal Article -
13
Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci
Published in Molecular psychiatry (01-10-2020)“…Smoking is a major heritable and modifiable risk factor for many diseases, including cancer, common respiratory disorders and cardiovascular diseases. Fourteen…”
Get full text
Journal Article -
14
Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality
Published in European heart journal (07-05-2021)“…Abstract Aims Inflammation plays an important role in cardiovascular disease (CVD) development. The NOD-like receptor protein-3 (NLRP3) inflammasome…”
Get full text
Journal Article -
15
Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients: The Prospective, Randomized, Controlled ICD2 Trial
Published in Circulation (New York, N.Y.) (04-06-2019)“…BACKGROUND:Patients with end-stage renal disease who are undergoing dialysis are reported to be at high risk of sudden cardiac death (SCD), and to date, no…”
Get full text
Journal Article -
16
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis
Published in European heart journal (21-06-2020)“…Abstract Aims Lowering low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular risk irrespective of age, but the evidence is less strong for older…”
Get full text
Journal Article -
17
T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword
Published in Nature reviews cardiology (01-06-2019)“…The role of inflammation in cardiovascular disease (CVD) is now widely accepted. Immune cells, including T cells, are influenced by inflammatory signals and…”
Get full text
Journal Article -
18
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
Published in The American heart journal (01-11-2014)“…Background Following acute coronary syndrome (ACS), the risk for future cardiovascular events is high and is related to levels of low-density lipoprotein…”
Get full text
Journal Article -
19
Prognostic Value of Multislice Computed Tomography Coronary Angiography in Patients With Known or Suspected Coronary Artery Disease
Published in Journal of the American College of Cardiology (02-01-2007)“…Prognostic Value of Multislice Computed Tomography Coronary Angiography in Patients With Known or Suspected Coronary Artery Disease Gabija Pundziute, Joanne D…”
Get full text
Journal Article -
20
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Published in The New England journal of medicine (05-01-2012)“…In this trial, vorapaxar, a protease-activated–receptor 1 antagonist that inhibits thrombin-induced platelet activation, was not effective in reducing the…”
Get full text
Journal Article